Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC

Biosimilar-eligible biologic indications (oncology supportive care, immunology, allergic asthma)

$40.0B US Market

Disease Overview

The biosimilars market addresses a wave of biologic loss-of-exclusivity (LOE) covering high-value reference products across oncology supportive care (G-CSFs like filgrastim and pegfilgrastim used to manage chemotherapy-induced neutropenia), immunology (anti-TNF and anti-IL agents like adalimumab/Humira), and allergic asthma/chronic spontaneous urticaria/CRSwNP (anti-IgE agents like omalizumab/Xolair). Reference biologics treat tens of millions of patients globally and represent over $300 billion in projected biologics LOE volume across the next decade per Amneal's investor commentary. In the US, biosimilar uptake has accelerated since the 2023 Humira biosimilar launches, with payers driving formulary substitution to capture 30-60% list-price discounts. Unmet need is centered on access and affordability rather than novel mechanism: branded biologics consume disproportionate Medicare Part B and commercial spend, and biosimilar adoption is increasingly the policy lever to expand patient access. Key commercial dynamics include interchangeability designations, payer contracting, the IRA's biosimilar reimbursement adjustments under Part B, and 351(k) regulatory complexity that limits the number of credible end-to-end developers.

Competitive Landscape

Biosimilars development is concentrated in a handful of vertically integrated players. Sandoz (Novartis), Celltrion, Samsung Bioepis, Pfizer, Teva, Coherus, Biocon Biologics, Alvotech, and Organon (now being acquired by Sun Pharma) lead the global field. Kashiv is among the few US-based companies with end-to-end development, manufacturing, and FDA-approved biosimilars (Releuko/filgrastim-ayow approved March 2022; Fylnetra/pegfilgrastim-pbbk approved May 2022; ADL-018 omalizumab biosimilar BLA filed September 2025). Differentiation centers on US manufacturing footprint (a tariff and supply-chain hedge), interchangeability designations, and pipeline cadence. Sun-Organon and Amneal-Kashiv announced within the same week signal a consolidation cycle ahead of the >$300B biologic LOE wave. Five to ten years post-close, Amneal's path depends on whether the combined entity can execute the stated 12+ commercial biosimilars by 2030 against scale leaders like Sandoz and Samsung Bioepis; success would re-rate AMRX from a generics platform to a top-7 global biosimilars franchise.